Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting
21.6.2024 23:30:00 EEST | Business Wire | Press release
Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man.
The ordinary resolutions below were passed by shareholders, with voting results as follows:
Ordinary Resolutions | For | %
| Against | %
| Abstain | %
|
To receive the Company’s accounts for the financial year ended December 31, 2023 | 60,456,134 | 100.00% | 0 | 0.00% | 264 | 0.00% |
To re-elect John Dowd as a Class I Director of the Company | 60,375,930 | 99.87% | 79,177 | 0.13% | 1,291 | 0.00% |
To re-elect Govind Friedland as a Class I Director of the Company | 59,713,208 | 98.77% | 79,319 | 0.13% | 663,871 | 1.10% |
To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company | 60,314,469 | 99.77% | 81,886 | 0.14% | 60,043 | 0.10% |
A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM.
If you would like to sign up for Lifezone Metals news alerts, please register here.
About Lifezone Metals
At Lifezone Metals (NYSE: LZM), our mission is to provide cleaner and more responsible metals production and recycling. Using a scalable platform underpinned by our Hydromet Technology, we offer the potential for lower energy, lower emission and lower cost metals production compared to traditional smelting.
Our Kabanga Nickel Project in Tanzania is believed to be one of the world's largest and highest-grade undeveloped nickel sulfide deposits. By pairing with our Hydromet Technology, we are working to unlock a new source of LME-grade nickel, copper and cobalt for the global battery metals markets, to empower Tanzania to achieve full in-country value creation and become the next premier source of Class 1 nickel. A Definitive Feasibility Study for the project is due for completion in Q3 2024.
Through our US-based, platinum, palladium and rhodium recycling partnership, we are working to demonstrate that our Hydromet Technology can process and recover platinum group metals from responsibly sourced spent automotive catalytic converters in a cleaner and more efficient way than conventional smelting and refining methods.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240621932210/en/
Contacts
Investor Relations – North America
Evan Young
SVP: Investor Relations & Capital Markets
evan.young@lifezonemetals.com
Investor Relations – Europe
Ingo Hofmaier
Chief Financial Officer
ingo.hofmaier@lifezonemetals.com
Media Enquiries
David Petrie
Manager: Corporate Communications
david.petrie@lifezonemetals.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 17:00:00 EET | Press release
For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passion and Perseverance, a new documentary from global technology and data company Experian that explores how access to financial tools, technology and support can help people overcome obstacles and pursue new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105341861/en/ Behind-the-scenes photo from the filming of RECLAIM: Stories of Passion and Perseverance, an Experian documentary. Brody Frye, who received care from The MetroHealth System in Cleveland, Ohio, is featured in the film’s story about healthcare innovation and the p
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 16:32:00 EET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 16:00:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 16:00:00 EET | Press release
Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation has always been at the forefront of everything we do,” said Jim Huether, CEO of Hyperice. “Heat and dynamic air compressio
European Commission expands license for Alfasigma’s Jyseleca ® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 16:00:00 EET | Press release
The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financial and investor media only. Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Commission (EC) has approved an additional indication to Jyseleca® (filgotinib) 200 mg and 100 mg film-coated tablets, an oral once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. A submission for UK approval has been made to the Medicines and Healthcare products Regulatory Agency (MHRA) and is under review. The European Commission’s approval is based on data that support a favourable benefit-risk profile for filgotinib, including efficacy and safety fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom